Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 70710-1655

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 70710-1655). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 01)

Chemical structure diagram of pemetrexed disodium, showing the molecular arrangement including sodium (Na) atoms and the 2.5 molecules of water of hydration (2.5 H2O) indicated.*

FDA Label Image

Figure 1 (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 02)

A Kaplan-Meier survival curve showing overall survival percentage over time in months. Two treatment arms are compared: P+P+C (pemetrexed + pembrolizumab + platinum chemotherapy) and P+C (pemetrexed + platinum chemotherapy + placebo). The graph includes a risk table below indicating the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 2 (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 03)

A survival curve graph comparing two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC) over a survival time of 0 to 30 months. The y-axis represents survival probability ranging from 0 to 1. A table below the graph shows the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 3 (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 04)

A survival probability chart comparing two treatment regimens over time in months. The chart plots survival probability on the vertical axis against survival time in months on the horizontal axis. Two lines represent treatments: solid for Pemetrexed plus Cisplatin (PC) and dashed for Gemcitabine plus Cisplatin (GC). Below the graph is a table showing the number of patients at risk for each treatment group at various time points up to 30 months.*

FDA Label Image

Figure 4 (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 05)

A Kaplan-Meier survival curve chart showing survival probability over time (in months) for two groups: Pemetrexed and Placebo. The chart includes a table of patient counts at risk for each time point below the X-axis. The Pemetrexed group shows a higher survival probability compared to placebo over the time period up to about 42 months.*

FDA Label Image

Image (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 06)

A Kaplan-Meier survival curve showing the survival probability over time in months for patients treated with pemetrexed compared to placebo. The chart includes a solid line for pemetrexed and a dotted line for placebo, with a table below indicating the number of patients at risk at various time points up to 42 months.*

FDA Label Image

Image (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 07)

A Kaplan-Meier survival curve chart showing survival probability over time in months for patients treated with pemetrexed versus placebo. The chart includes the number of patients at risk at various time points for both treatment groups. The solid line represents pemetrexed, and the dotted line represents placebo.*

FDA Label Image

Image (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 08)

A Kaplan-Meier survival curve chart comparing survival probability over time (in months) between patients treated with pemetrexed and placebo. The chart includes lines for pemetrexed and placebo groups, showing survival probabilities from 0 to 42 months, with a table below listing the number of patients at risk at various time points for each group.*

FDA Label Image

Image (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 09)

A survival probability curve comparing pemetrexed and placebo over time in months, with survival probability on the y-axis and survival time on the x-axis. The graph includes patient risk counts at various time points for both pemetrexed and placebo groups, illustrating a decline in survival probability over approximately 36 months.*

FDA Label Image

Image (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 10)

A Kaplan-Meier survival curve chart depicting survival probability over time in months. It compares two groups: patients treated with pemetrexed plus cisplatin and those given a placebo. The chart includes the number of patients at risk at various time intervals for each group.*

FDA Label Image

100 mg Container Label (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 11)

Label for Pemetrexed for Injection, USP 100 mg/vial, lyophilized powder for reconstitution, for intravenous use. It is a single-dose vial labeled as a cytotoxic agent. Manufactured by Zydus Hospira Oncology Private Limited, India, and distributed by Zydus Pharmaceuticals USA Inc. The label includes storage instructions, cautionary information, lot and expiration date fields, and a barcode.*

FDA Label Image

100 mg Carton Label (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 12)

Packaging label for Pemetrexed for Injection, USP 100 mg/vial. The product is a lyophilized powder for intravenous injection supplied in single-dose vials. The label includes drug reconstitution instructions and storage conditions. It is manufactured by Zydus Hospira Oncology Private Limited, India, and distributed by Zydus Pharmaceuticals USA, Inc. The label features the Zydus logo and NDC 70710-1654-1.*

FDA Label Image

500 mg Container Label (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 13)

Label for Pemetrexed for Injection, USP 500 mg/vial lyophilized powder for solution, intravenous use only. It is a single-dose vial with a caution for cytotoxic use. The label states it is manufactured by Zydus Hospira Oncology Private Limited, India, and distributed by Zydus Pharmaceuticals USA Inc., Pennington, NJ. Storage instructions and regulatory notes are included.*

FDA Label Image

500 mg Carton Label (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 14)

Packaging label for Pemetrexed for Injection, USP 500 mg/vial, a lyophilized powder for intravenous injection. The label shows it is a single-dose vial manufactured by Zydus Hospira Oncology Private Limited, distributed by Zydus Pharmaceuticals USA Inc. Storage and reconstitution instructions are included, with a caution that it is a cytotoxic agent.*

FDA Label Image

1000 mg Container Label (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 15)

Label for Pemetrexed for Injection USP 1000 mg/vial, a single-dose vial for intravenous use by Zydus Pharmaceuticals USA Inc. The label includes storage instructions, a caution that it is a cytotoxic agent, manufacturer details (Zydus Hospira Oncology Private Limited, India), and barcode. The vial contains lyophilized powder for injection with lot and expiration date fields.*

FDA Label Image

1000 mg Carton Label (Bf1de3fa E7f8 4beb Beeb 6272709d13f2 16)

Label for Pemetrexed for Injection, USP 1000 mg/vial, lyophilized powder for intravenous use only. This single-dose vial is manufactured by Zydus Hospira Oncology Private Limited and distributed by Zydus Pharmaceuticals (USA) Inc. The label includes reconstitution instructions, storage conditions, and a caution that it is a cytotoxic agent. NDC 70710-1674-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.